Megakaryoblasts
Hematopoietic stem cells (HSC) differentiate into proliferating early megakaryocytic lineage cells called megakaryoblasts (MB). The rate of differentiation into MBs is known to be increased by IL-6, IL-3, IL-11 and TPO 1, 2 . Of these, IL-6 and IL-11 are known to act via the JAK1 pathway and IL-3 and TPO act via the JAK2 pathway. IL-6 and TPO are considered in our model
In the model, the MBs are assumed to be produced from a constant pool of HSCs at a basal rate (
). This rate is augmented under the influence of IL-6 and thrombopoietin (TPO). The process of differentiation of MBs into MKs is divided into early, mid and late stages (MB, MB1 and MB2). The maturation process is assumed to take about 8 days 3, 4 . Late MBs then differentiate into MKs.
The effective IL6 and TPO concentration in the presence of the drug are shown as IL6drug and TBMdrug.
Megakaryocytes
Megakaryocytes (MK) produced from MBs take about 5 days to undergo polyploidization or endomitosis and form platelets 5 . This process is also divided into early, mid and late stages -MK, MK1 and MK2 in the model. Late MKs then differentiate into platelets and the rate of differentiation is influenced by TPO levels 6 . TPO independent mechanisms for MK differentiation are bundled into the basal differentiation rate. Megakaryocyte expansion is kept in check by TPO 7 . This mechanism is explicitly incorporated into the model and because proliferation term is added to the equation, we added in a degradation term dMK. This term has been added only to MK equation as a lumping phenomenon representing decay in this species in the bone marrow compartment.
Platelets
New platelets (Pnew) formed from MKs age in blood. The aged platelets (Paged) are then either taken up by the immune system or undergo apoptosis or are internalized by the AMR receptor on the liver to produce more TPO. The rate of internalization of desialylated platelets by AMR is approximated from mouse data in literature 8 .
Thrombopoietin
TPO is produced primarily in the liver and is transported to the blood and bone marrow. In the model, TPO in the liver, blood and bone marrow are modeled as separate species with a parameter for rate of transit of TPO from one compartment to the other. In the liver, aged platelets through a JAK2-STAT3 pathway produce more TPO.
Grozovsky et al show an increase in TPO mRNA in the liver and Plasma concentration of TPO on transplanting aged platelets from an AMR deficient mouse into a WT mouse. Maximum rate of TPO production through this pathway is estimated from here. IL-6 also produces TPO through a JAK1 -STAT3 pathway. Experiments in mice and human hepatocyte cultures 9, 10 have shown an increase in TPO production in the presence of IL-6 in the environment. Maximum rate of TPO production through this pathway is estimated from these experiments.
TPO in the blood is taken up by the platelets and internalized using the myeloproliferativeleukemia (mpl) receptor. Old platelets consume less TPO compared to the new platelets. This is captured by reducing the rate of consumption of TPO by aged platelets by a factor f. Experiments showing internalization of the mpl receptor by platelets and megakaryocytes 11, 12 are used to determine estimates for rate of TPO internalization.
In the bone marrow, TPO is taken up by the MK and MB cells through the mpl receptor aiding the process of producing more platelets. Degradation rate of TPO in the model is estimated based on the half-life 13, 14 reported in literature. Rate of production is estimated by optimizing the steady state to value reported in literature 15, 16 . In the equation below, f is a fraction (constant) representing the reduction in the rate of internalization of TPO by aged platelets.
Interleukin -6
A constant rate of IL-6 production and a first order degradation rate are assumed based on the steady state levels reported in literature in patients 17 .
Hill coefficients for equations in the model (β, ε, γ) are fixed at 2 except for the ones describing the sensitivity of MB production to TPO concentration in the bone marrow (α). On exploring the parameter space, a high value (α = 6) gave rise to oscillations in platelet count whereas setting α to 1 gave a non-oscillatory steady state.
